Protocol deviation [Study As­sess­ment]

posted by Ghousia Saba – Pakistan, 2014-10-17 14:37 (3477 d 18:17 ago) – Posting: # 13742
Views: 4,657

Dear All


If we conduct the bioequivalence with clinical end points and there are deviations in the conduct of the study e.g. included patients do not meet the entry criteria or change in dose timing. however, the results show that these deviations have not effected the outcomes and there is treatment success. however, these may result in AE.

Should we include such subjects in final data analysis for BE or these should be excluded?


Regards
Ghousia


Edit: Category and subject line modified. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
22,993 posts in 4,828 threads, 1,656 registered users;
116 visitors (0 registered, 116 guests [including 1 identified bots]).
Forum time: 08:55 CEST (Europe/Vienna)

Never never never never use Excel.
Not even for calculation of arithmetic means.    Martin Wolfsegger

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5